ASCO 2022 Conference Coverage


 

ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable HCC

73 views
July 9, 2022
Comments 0
Login to view comments. Click here to Login